SELLAS Life Sciences (SLS) Net Income towards Common Stockholders (2010 - 2026)
SELLAS Life Sciences (SLS) posted quarterly Net Income towards Common Stockholders of -$15.1 million for Q1 2026, down 140.35% year-over-year from $37.3 million in Q1 2025, and down 80.17% quarter-over-quarter from -$8.4 million in Q4 2025.
Powered by 
Analysis
SELLAS Life Sciences (SLS) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Net Income towards Common Stockholders for 17 consecutive years, with -$15.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 140.35% year-over-year to -$15.1 million; the TTM figure through Mar 2026 stood at -$39.6 million (down 39.35% YoY), while the FY2025 annual figure was -$51.1 million, up 2.42% from the prior year.
- Net Income towards Common Stockholders fell to -$15.1 million in Q1 2026 per SLS's latest filing, from -$8.4 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$6.3 million in Q1 2025 and bottomed at -$16.8 million in Q1 2022.
- Historically, Net Income towards Common Stockholders has averaged -$9.3 million across 5 years, with a median of -$8.7 million in 2022.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders sank 600.58% — and 2025, when it soared 35.73%.
- SELLAS Life Sciences' Net Income towards Common Stockholders stood at -$9.6 million in 2022, then advanced by 14.19% to -$8.3 million in 2023, then increased by 15.21% to -$7.0 million in 2024, then declined by 19.05% to -$8.4 million in 2025, then tumbled by 80.17% to -$15.1 million in 2026.
- Business Quant data shows SLS's Net Income towards Common Stockholders at -$15.1 million in Q1 2026, -$8.4 million in Q4 2025, and -$7.3 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -13.27 Mn |
| 10 | SELLAS Life Sciences | 2.62 Bn | 2.62 Bn | - | -9.61 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -9.61 Mn |
| Mar 31, 2026 | -8.41 Mn |
| Dec 31, 2025 | -7.66 Mn |
| Sep 30, 2025 | -6.79 Mn |
| Jun 30, 2025 | -6.60 Mn |
| Mar 31, 2025 | -5.81 Mn |
| Dec 31, 2024 | -6.74 Mn |
| Sep 30, 2024 | -7.11 Mn |
| Jun 30, 2024 | -7.47 Mn |
| Mar 31, 2024 | -9.57 Mn |
| Dec 31, 2023 | -8.14 Mn |
| Sep 30, 2023 | -9.27 Mn |
| Jun 30, 2023 | -8.84 Mn |
| Mar 31, 2023 | -11.28 Mn |
| Dec 31, 2022 | -9.45 Mn |
| Sep 30, 2022 | -7.15 Mn |
| Jun 30, 2022 | -8.62 Mn |
| Mar 31, 2022 | -16.74 Mn |
| Dec 31, 2021 | -6.60 Mn |
| Sep 30, 2021 | -7.09 Mn |